MedTrace Logo

Survival Benefits of Neoadjuvant Systemic Chemotherapy in Muscle Invasive Bladder Cancer

NCT06727214 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 87

Last updated 2025-09-30

No results posted yet for this study

Summary

Muscle-invasive bladder cancer (MIBC) is an aggressive disease with a high-risk of early metastasis and cancer specific mortality. The gold standard treatment of MIBC is radical cystectomy (RC) in conjunction with concomitant bilateral pelvic lymphadenectomy . While radical cystectomy remains a primary management strategy for MIBC, high rates of recurrence with surgery alone highlight the likelihood of occult micrometastatic disease at the time of diagnosis. Due to the development and implementation of neoadjuvant chemotherapy prior to radical cystectomy, the prognosis for MIBC patients undergoing radical cystectomy has improved .

Conditions

  • Bladder Urothelial Carcinoma

Interventions

DRUG

Chemotherapy with platine

medical records that patients received neoadjuvant systemic chemotherapy platine based

Sponsors & Collaborators

  • Sara Mahmoud Ahmed Mahmoud

    lead OTHER

Principal Investigators

  • Rehab Farouk Mohamed, Professor · Assiut University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-04
Primary Completion
2026-11-04
Completion
2026-12-01
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06727214 on ClinicalTrials.gov